| Literature DB >> 22666569 |
Sigrid Beitland1, Kjetil Sunde, Harald Moen, Ingrid Os.
Abstract
Introduction. Acute kidney injury (AKI) necessitating continuous renal replacement therapy (CRRT) is a severe complication in trauma patients (TP). We wanted to assess daily duration of CRRT and its impact on uremic control in TP. Material and Methods. We retrospectively reviewed adult TP, with or without rhabdomyolysis, with AKI undergoing CRRT. Data on daily CRRT duration and causes for temporary stops were collected from the first five CRRT days. Uremic control was assessed by daily changes in serum urea (Δurea) and creatinine (Δcreatinine) concentrations. Results. Thirty-six TP were included with a total of 150 CRRT days, 17 (43%) with rhabdomyolysis. The median (interquartile range (IQR)) time per day with CRRT was 19 (15-21) hours. There was a significant correlation between daily CRRT duration and Δurea (r = 0.60, P≤0.001) and Δcreatinine (r = 0.43; P = 0.012). CRRT pauses were caused by filter clotting (54%), therapeutic interventions (25%), catheter related problems (10%), filter timeout (6%), and diagnostic procedures (6%). Rhabdomyolysis did not affect the CRRT data. Conclusions. TP undergoing CRRT had short daily CRRT duration causing reduced uremic control. Clinicians should modify their daily clinical practice to improve technical skills and achieve sufficient dialysis dose.Entities:
Year: 2012 PMID: 22666569 PMCID: PMC3362819 DOI: 10.1155/2012/869237
Source DB: PubMed Journal: Crit Care Res Pract ISSN: 2090-1305
Figure 1Flow chart of 36 adult trauma patients treated with continuous renal replacement therapy for acute kidney injury grouped with and without rhabdomyolysis.
Patient characteristics: Trauma patients with acute kidney injury with continuous renal replacement therapy (CRRT) grouped with and without rhabdomyolysis (n = 36).
| Total ( | Rhabdomyolysis ( | Not rhabdomyolysis ( |
| |
|---|---|---|---|---|
|
| ||||
| Age (years) | 48 (30–65) | 35 (23–51) | 57 (44–68) | 0.01 |
| Male gender | 31 (86) | 17 (100) | 14 (74) | 0.02 |
| SAPS II score | 41 (32–48) | 38 (31–48) | 41 (32–49) | 0.90 |
| ISS score | 34 (26–47) | 43 (17–50) | 34 (27–41) | 0.24 |
|
| ||||
| Fluid overload | 19 (53) | 8 (47) | 11 (58) | 0.52 |
| Hyperkalemia | 20 (56) | 9 (53) | 11 (58) | 0.77 |
| Acidosis | 15 (42) | 3 (18) | 12 (63) | 0.01 |
| Uremia | 9 (25) | 4 (24) | 5 (26) | 0.85 |
| Rhabdomyolysis | 17 (47) | 17 (100) | 0 (0) | <0.01 |
|
| ||||
| Diuresis (mL/day) | 536 (256–1692) | 522 (252–2060) | 550 (255–1410) | 0.80 |
| Serum potassium (mmol/L) | 5.0 (4.2–5.5) | 4.4 (4.0–5.7) | 5.1 (4.8–5.5) | 0.20 |
| Serum urea (mmol/L) | 17.8 (12.5–28.4) | 13.6 (10.6–25.0) | 22.2 (16.3–29.8) | 0.07 |
| Serum creatinine ( | 249 (204–376) | 247 (198–483) | 269 (215–361) | 0.95 |
| Serum creatine kinase (U/L) | 4638 (460–24414) | 24415 (9660–45740) | 603 (135–2152) | <0.01 |
|
| ||||
| Median daily CRRT duration (hours) | 18.6 (14.9–21.3) | 16.3 (12.4–20.0) | 19.7 (15.6–21.8) | 0.19 |
| Median Δurea | -0.05 (−0.12–0.09) | -0.06 (−0.19–0.03) | -0.05 (−0.08–0.11) | 0.20 |
| Median Δcreatinine | 0.05 (−0.04–0.17) | 0.03 (−0.17–0.15) | 0.12 (0.01–0.17) | 0.21 |
| Filter clotting pauses | 68 (54) | 36 (55) | 32 (53) | 0.90 |
| Therapeutic pauses | 32 (25) | 25 (38) | 7 (12) | <0.01 |
| Catheter-related pauses | 12 (10) | 3 (5) | 9 (15) | 0.05 |
| Filter timeout pauses | 7 (6) | 1 (2) | 6 (10) | 0.04 |
| Diagnostic pauses | 7 (6) | 5 (8) | 2 (3) | 0.30 |
|
| ||||
| Dialysis-dependent 3 months | 0 (0) | 0 (0) | 0 (0) | n.c. |
| Dialysis-dependent 1 year | 0 (0) | 0 (0) | 0 (0) | n.c. |
| Mortality 3 months | 11 (31) | 3 (18) | 8 (42) | 0.11 |
| Mortality 1 year | 13 (36) | 4 (24) | 9 (47) | 0.14 |
Categorical data are presented as number (percent) and compared using Pearson chi-square test. Continuous data are expressed as median (interquartile range) and are compared using 2-tailed Mann-Whitney U test. SAPS II: simplified acute physiology score II. ISS: injury severity score. n.c.: not calculated. See text for other definitions.
Individual data: Trauma patients with acute kidney injury with continuous renal replacement therapy (CRRT) grouped with and without rhabdomyolysis (n = 36).
| Patient number | Rhabdomyolysis | CRRT days | Median daily CRRT duration | Median Δurea | Median Δcreatinine |
|---|---|---|---|---|---|
| 1 | No | 5 | 21,1 | −0,05 | −0,05 |
| 2 | No | 5 | 19,7 | 0,10 | 0,22 |
| 3 | No | 5 | 22,3 | 0,15 | 0,15 |
| 4 | No | 5 | 22,3 | 0,12 | 0,17 |
| 5 | Yes | 5 | 16,8 | 0,03 | 0,14 |
| 6 | Yes | 5 | 20,8 | 0,01 | 0,01 |
| 7 | No | 3 | 18,7 | −0,10 | 0,16 |
| 8 | Yes | 5 | 22,8 | 0,03 | 0,04 |
| 9 | No | 5 | 18,7 | 0,11 | 0,28 |
| 10 | No | 5 | 21,8 | −0,08 | 0,02 |
| 11 | Yes | 5 | 19,2 | 0,23 | 0,25 |
| 12 | No | 4 | 16,1 | −0,01 | 0,13 |
| 13 | Yes | 1 | 9,1 | ||
| 14 | No | 5 | 23,8 | −0,14 | 0,01 |
| 15 | Yes | 4 | 16,1 | 0,17 | 0,18 |
| 16 | No | 5 | 9,8 | −0,23 | −0,12 |
| 17 | Yes | 5 | 10,3 | −0,18 | −0,02 |
| 18 | No | 5 | 21,4 | 0,08 | 0,03 |
| 19 | Yes | 4 | 18,5 | −0,14 | −0,18 |
| 20 | Yes | 4 | 15,8 | −0,02 | 0,21 |
| 21 | Yes | 1 | 24,0 | ||
| 22 | No | 2 | 15,6 | −0,06 | 0,05 |
| 23 | Yes | 5 | 16,3 | −0,20 | −0,24 |
| 24 | No | 5 | 23,5 | 0,17 | 0,25 |
| 25 | Yes | 5 | 18,5 | −0,10 | −0,05 |
| 26 | No | 4 | 11,5 | −0,08 | −0,15 |
| 27 | Yes | 2 | 16,1 | 0,03 | 0,08 |
| 28 | No | 5 | 14,4 | −0,09 | −0,03 |
| 29 | No | 5 | 19,4 | 0,04 | 0,01 |
| 30 | No | 4 | 14,6 | −0,07 | 0,18 |
| 31 | Yes | 5 | 13,0 | −0,30 | −0,32 |
| 32 | Yes | 1 | 24,0 | ||
| 33 | No | 5 | 19,9 | 0,18 | 0,12 |
| 34 | Yes | 3 | 11,8 | −0,35 | 0,05 |
| 35 | No | 5 | 20,9 | −0,07 | 0,12 |
| 36 | Yes | 3 | 8,6 | −0,19 | −0,17 |
Δurea = (Ureaday N−Ureaday N + 1)/Ureaday N where Ureaday N is the serum concentration of urea at day N, and Urea day N + 1 is the serum concentration of urea at day N+1.
Δcreatinine = (Creatinineday N−Creatinineday N + 1)/Creatinineday N where Creatinineday N is the serum concentration of creatinine at day N, and Creatinineday N + 1 is the serum concentration of creatinine at day N+1.
Figure 2Scattergram of median daily CRRT duration and median Δurea in the total population and the subgroups with and without rhabdomyolysis. Linear regression analysis showed a significant relationship between median daily CRRT duration and median Δurea in the whole group, r = 0.60, P < 0.001.
Figure 3Scattergram of median daily CRRT duration and median Δcreatinine in the total population and the subgroups with and without rhabdomyolysis. Linear regression analysis showed a significant relationship between median daily CRRT duration and median Δcreatinine in the whole group, r = 0.43, P = 0.012.